Navigation Links
BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:10/31/2008

Peramivir was generally safe and well-tolerated at these dose levels.

Detailed results will be submitted to an upcoming medical meeting.

-- BioCryst reported top-line results from the completed Phase 2a trial of

BCX-4208 in subjects with moderate to severe plaque psoriasis were

consistent with interim findings. BCX-4208, a potent, rationally

designed, orally available purine nucleoside phosphorylase inhibitor,

met its primary endpoint of safety and tolerability and displayed

dose-dependant reductions in peripheral blood lymphocyte counts. The

pharmacokinetic and pharmacodynamic results suggest that BCX-4208 may

have utility in diseases dependant on T-cells, B-cells or uric acid.

The Phase 2a results have been accepted for presentation at the 50th

American Society of Hematology Annual Meeting and Exposition (ASH),

which will be held in San Francisco, December 6-9, 2008.

-- The forodesine HCl pivotal trial in cutaneous T-cell lymphoma (CTCL)

continues to enroll subjects with CTCL stages IIB through IVA who have

failed three systemic therapies. The multinational study is evaluating

once daily oral forodesine HCL treatment and is being conducted in

accordance with a Special Protocol Assessment agreement between the U.S.

Food and Drug Administration and BioCryst. A laboratory study of

forodesine HCl in leukemia cells has been accepted for presentation at

ASH.

Conference Call and Web cast

BioCryst's management team will host a conference call and Web cast on Friday, October 31, 2008, at 8:30 a.m. Eastern Time to discuss the financial results and recent developments within the Company's programs. To participate in the conference call, please dial 1-800-860-2442 (United States) or 1-412-858-4600 (International). No passcode is needed for the call. The Web ca
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
2. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
3. BioCryst to Present at the JMP Healthcare Focus Conference
4. BioCryst to Present at UBS 2008 Global Life Sciences Conference
5. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
6. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
9. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
10. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
11. BioCryst to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... the development of autologous cell therapies, announced today that RepliCel,s ... InvestMNT conference held in Minneapolis, Minnesota ... Hall,s presentation will highlight RepliCel,s 18-month milestones including CE Mark ... Europe , clinical data from both RCT-01 (tendon) and ...
(Date:7/31/2015)... China Cord Blood Corporation (NYSE: CO) ("CCBC" ... provider of cord blood collection, laboratory testing, hematopoietic stem ... that the Company has filed its Annual Report on ... The filed Form 20-F includes audited financial statements for ... 20-F can be accessed by visiting the U.S. Securities ...
(Date:7/30/2015)... Mass. , July 30, 2015   ... solutions for the interpretation and analysis of genomic ... Matthew Fischer has joined the company as ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... capabilities to integrate, interpret, analyze and explore complex ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... successful completion of a field clinical study of its canine osteoarthritis stem cell ... with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US ...
Breaking Biology Technology:RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3
... point to accelerated growth in China ,s domestic market:  rising corporate ... government policy continues to urge greater consumption of goods.  At Philadelphia,s Cira ... executives and managers can learn how to get into the game at ... , , ...
... unique device based on sniffing inhaling and exhaling ... to navigate wheelchairs or communicate with their loved ones. ... to create a sort of ,third hand, to assist ... Sobel, electronics engineers Dr. Anton Plotkin and Aharon Weissbrod ...
... , PHILADELPHIA - Collaboration by chemists, physicists and ... created a simple and inexpensive method to rapidly ... BNSLs, by crystallizing a mixture of nanocrystals on ... new and spontaneous way to grow long-range-ordered BNSL ...
Cached Biology Technology:Orchestrall Sponsors 'China Business Toolbox': Brings Focus to the 'How and When' of China Market Access 2Orchestrall Sponsors 'China Business Toolbox': Brings Focus to the 'How and When' of China Market Access 3New invention at the Weizmann Institute 2New invention at the Weizmann Institute 3Penn collaboration leads to simpler method for building varieties of nanocrystal superlattices 2Penn collaboration leads to simpler method for building varieties of nanocrystal superlattices 3
(Date:7/7/2015)... , July 7, 2015  Based on ... Frost & Sullivan recognizes Credence ID, LLC with ... Entrepreneurial Company of the Year Award. Credence ID ... aid in its mission of offering enrollment and ... globally. As Credence ID was formed by experts ...
(Date:7/2/2015)... Sweden , July 2, 2015 ... sensors FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... 2015. The sensors will be used by smartphone manufacturers in ... MSEK is included in the communicated revenue guidance of approximately ...
(Date:6/26/2015)... -- ATL Technology, LLC, a top provider of electromechanical contract ... solutions, headquartered in Springville, Utah , has ... corporation with locations in Santa Clara, ... ). This acquisition will incorporate MedConx,s manufacturing ... Technology,s existing facility in Costa Rica , ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2
... A multi-institutional team of researchers, including scientists at Albert ... a prestigious National Institutes of Health (NIH) "Glue Grant" ... function of unknown enzymes identified in genome-sequencing projects. ... and chemical diversity that exists in nature and may ...
... Ore. Scientists are a valuable and trusted source ... too often do an inadequate job of bringing that ... non-technical, credible and neutral format. An analysis of ... "marine reserves" off the California coast offers insights into ...
... New York, 21 May 2010 - Activities taking ... United Nations Environment Programme with financial support from the ... 22 May] reflect the growing recognition of the importance ... the ecosystems we all depend upon. The ...
Cached Biology News:NIH funds multicenter 'glue grant' to study enzyme function 2Scientists need to be more proactive, effective at public communication 2Scientists need to be more proactive, effective at public communication 3TEEB study leader emphasizes urgent need for action on biodiversity loss 2
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
NAP-2 (5C7)...
... RACE (rapid amplification of cDNA ends) technique ... 5' and 3' cDNA ends. The GeneRacer ... Transcriptase (RT) for improved amplification of the ... mRNA. The RNase H portion of SuperScript ...
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Biology Products: